Please assess the completion status of the following clinical trial:

Trial Title: A Study of Adalimumab After Dose Escalation in Japanese Subjects With Crohn's Disease

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Subject ≥ 15 years of age at the time of informed consent.~* Subject with Crohn's disease who received induction treatment of commercially available Humira® (160 mg initially and 80 mg at 2 weeks after initial dose), achieved response after initial dose, and then lost response during maintenance treatment with Humira®.~* Subject with elevated C-reactive Protein (CRP) at Screening.~* If female, subject is either not of childbearing potential, defined as postmenopausal for at least 1 year or surgically sterile (bilateral tubal ligation, bilateral oophorectomy and/or hysterectomy) or is of childbearing potential and is practicing an approved method of birth control throughout the study and for 150 days after the last dose of study drug.~* Subject has a negative tuberculosis (TB) screening assessment. If the subject has evidence of a latent TB infection; the subject must initiate and complete a minimum of 21 days of an ongoing TB prophylaxis (in such case, screening period can be prolonged until 21 days past after initiation of prophylaxis and study drug is administered) or have documented completion of a full course of TB prophylaxis, prior to Week 0.~Exclusion Criteria:~* Subject with suspicion of colitis other than Crohn's disease.~* Subject with an ostomy or ileoanal pouch. (Subjects with a previous ileo-rectal anastomosis are not excluded).~* Subject with abscess or suspicion of abscess, or subject with infection(s).

- Gender: ALL
- Minimum Age: 15 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Adalimumab 80 mg (Type: EXPERIMENTAL): All participants were to receive subcutaneous injections of open-label adalimumab 80 mg every other week from Week 0 to Week 50.

Based on this trial design, predict the completion outcome and termination type (if applicable).